Product logins

Find logins to all Clarivate products below.


Physician and Payer Perspectives on Prescribing and Patient Access

China has long wrestled with an increasing prevalence in respiratory diseases that has accompanied its economic growth and development. As a result of poor air quality, the overall disease burden of asthma in China has increased among the rapidly urbanizing population of 1.3 billion. Today, China has the world’s highest asthma mortality rate, according to the Asia Asthma Development Board. Unfortunately, treatment options for asthma patients remain similar to those available ten years ago. The market is dominated by long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICS FDCs). Many newer drugs, which are available in mature pharmaceutical markets, such as the once-daily LABA/ICS FDC Relvar (GlaxoSmithKline’s vilanterol/fluticasone), and targeted therapies such as Xolair (Novartis’s omalizumab), are not yet available in China, leaving pulmonologists desperate for novel treatments that can help patients achieve better disease control. The likely high cost of emerging therapies will be met with payer-imposed reimbursement restrictions. New therapies will also have to contend with the impending entry of generic versions of key therapies. In the current economic climate, drug manufacturers must overcome these and other challenges to gain access to China’s increasingly cost-conscious pharmaceutical market.

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…